$36.2 Million is the total value of Asymmetry Capital Management, L.P.'s 23 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 51.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INSM | Buy | INSMED INC | $4,896,000 | -32.8% | 373,198 | +3.6% | 13.53% | +101.0% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $4,379,000 | +11.4% | 106,684 | +3.1% | 12.10% | +233.1% |
| PTCT | Sell | PTC THERAPEUTICS | $3,802,000 | -53.2% | 110,794 | -36.0% | 10.50% | +39.8% |
| PTLA | Sell | PORTOLA PHARMACEUTICALS INC | $3,321,000 | -50.5% | 170,129 | -32.5% | 9.18% | +48.1% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $2,075,000 | -53.8% | 57,486 | -21.2% | 5.73% | +38.2% |
| INCY | Sell | INCYTE CORP | $2,009,000 | -41.2% | 31,588 | -36.1% | 5.55% | +76.0% |
| CNC | Sell | CENTENE CORP | $1,867,000 | -48.1% | 16,189 | -34.9% | 5.16% | +55.1% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $1,715,000 | -58.0% | 6,884 | -55.1% | 4.74% | +25.6% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $1,469,000 | -48.3% | 20,571 | -11.1% | 4.06% | +54.5% |
| CVS | Sell | CVS CAREMARK CORP | $1,424,000 | -49.6% | 21,739 | -39.4% | 3.93% | +50.8% |
| INGN | New | INOGEN INC | $1,251,000 | – | 10,072 | +100.0% | 3.46% | – |
| PEN | Sell | PENUMBRA INC | $1,218,000 | -38.3% | 9,966 | -24.4% | 3.36% | +84.5% |
| DVA | Sell | DAVITA HEALTHCARE PARTNERS I | $1,089,000 | -79.3% | 21,156 | -71.2% | 3.01% | -38.1% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $932,000 | -78.5% | 97,294 | -72.8% | 2.58% | -35.6% |
| XLRN | Sell | ACCELERON PHARMA INC | $808,000 | -64.6% | 18,564 | -53.5% | 2.23% | +5.8% |
| HRTX | Sell | HERON THERAPEUTICS | $801,000 | -54.7% | 30,861 | -44.7% | 2.21% | +35.5% |
| NCNA | Sell | NUCANA PLC-ADRadr | $624,000 | -71.3% | 43,047 | -50.7% | 1.72% | -14.2% |
| VRAY | Sell | VIEWRAY INC | $589,000 | -71.9% | 96,964 | -56.7% | 1.63% | -16.0% |
| VRCA | Sell | VERRICA PHARMACEUTICALS INC | $512,000 | -59.0% | 62,882 | -18.2% | 1.42% | +22.6% |
| EQ | New | EQUILLIUM INC | $497,000 | – | 60,882 | +100.0% | 1.37% | – |
| BIO | New | BIO-RAD LABORATORIES | $405,000 | – | 1,745 | +100.0% | 1.12% | – |
| KDMN | Sell | KADMON HOLDINGS INC | $401,000 | -62.8% | 192,637 | -40.3% | 1.11% | +11.2% |
| DRRX | Sell | DURECT CORPORATION | $111,000 | -85.3% | 228,820 | -66.8% | 0.31% | -56.1% |
| GRTS | Exit | GRITSTONE ONCOLOGY INC | $0 | – | -20,000 | -100.0% | -0.26% | – |
| STIM | Exit | NEURONETICS INC | $0 | – | -45,292 | -100.0% | -1.34% | – |
| ECYT | Exit | ENDOCYTE | $0 | – | -96,297 | -100.0% | -1.58% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -105,072 | -100.0% | -1.62% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -31,379 | -100.0% | -1.65% | – |
| UROV | Exit | UROVANT SCIENCES LTD | $0 | – | -158,463 | -100.0% | -1.76% | – |
| IONS | Exit | IONIS PHARMACEUTICALS INC | $0 | – | -37,021 | -100.0% | -1.76% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -14,508 | -100.0% | -2.16% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -12,650 | -100.0% | -2.25% | – |
| OSUR | Exit | ORASURE TECHNOLOGIES INC | $0 | – | -179,496 | -100.0% | -2.56% | – |
| NTRA | Exit | NATERA INC | $0 | – | -124,517 | -100.0% | -2.75% | – |
| PFE | Exit | PFIZER INC | $0 | – | -68,311 | -100.0% | -2.78% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -33,211 | -100.0% | -3.06% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS | $0 | – | -22,144 | -100.0% | -3.44% | – |
| ACHC | Exit | ACADIA HEALTHCARE CO INC | $0 | – | -186,631 | -100.0% | -6.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.